Clinical Trials Logo

Clinical Trial Summary

Cerebral amyloid angiopathy (CAA) is a common form of cerebral small vessel disease, characterized by symptomatic intracerebral hemorrhage and cognitive impairment. However, no effective prevention and treatment strategies have been established. This study aims to evaluate the safety and efficacy of remote ischemic conditioning on patients with CAA.


Clinical Trial Description

CAA is a cerebrovascular disease caused by the deposition of β-amyloid in the walls of arteries, arterioles, and capillaries in the cerebral cortex and overlying leptomeninges. It is often associated with repeated lobar intracerebral hemorrhages, progressive cognitive decline, transient neurological symptoms and gait disturbances. No treatment is specific for symptomatic management of CAA up to date. Remote ischemic conditioning is a non-invasive strategy to protect the brain. The clinical trials have demonstrated that daily limb RIC seems to be potentially effective in patients with cerebral small-vessel disease in slowing cognition decline and reducing white matter hyperintensities. Thereby, investigators design this study to assess whether RIC has a beneficial effect on CAA. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05207475
Study type Interventional
Source Capital Medical University
Contact Xunming Ji, MD PhD
Phone 010-83199430
Email [email protected]
Status Recruiting
Phase N/A
Start date January 20, 2022
Completion date January 20, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03969732 - Multimodal Biomarkers for Diagnosis and Prognosis in CAA Phase 3
Not yet recruiting NCT05486897 - Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
Completed NCT03542656 - Application of Amyloid PET in Cerebral Amyloid Angiopathy Phase 3
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Recruiting NCT03464344 - Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. N/A
Completed NCT03824197 - Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD) N/A
Active, not recruiting NCT01856699 - Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy N/A
Completed NCT01821118 - Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy Phase 2
Recruiting NCT05394636 - Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy
Recruiting NCT04204642 - SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
Recruiting NCT04757597 - Remote Ischemic Conditioning for Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage N/A
Not yet recruiting NCT02361411 - Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy N/A
Not yet recruiting NCT04654026 - the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Completed NCT05082194 - Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Completed NCT04825808 - Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.
Withdrawn NCT01382849 - F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH) N/A
Recruiting NCT05499169 - Coach Pilot Study: Assessing Cognitive Function and Related Small Vessel Disease Markers After Intracerebral Hemorrhage